The clinical utility of aflibercept for diabetic macular edema
Michael W StewartDepartment of Ophthalmology, Mayo School of Medicine, Jacksonville, FL, USAAbstract: The treatment of center-involving diabetic macular edema (DME) has improved because of the proven efficacy of drugs that inhibit the effects of vascular endothelial growth factor (VEGF). The newest...
Guardado en:
Autor principal: | Stewart MW |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2015
|
Materias: | |
Acceso en línea: | https://doaj.org/article/858c1642809b40a2ac5ad0401170055d |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Role of implants in the treatment of diabetic macular edema: focus on the dexamethasone intravitreal implant
por: Cebeci Z, et al.
Publicado: (2015) -
Guidelines in the management of diabetic nerve pain clinical utility of pregabalin
por: Vinik AI, et al.
Publicado: (2013) -
Clinical utility of fixed combinations of sitagliptin–metformin in treatment of type 2 diabetes
por: Karen Barnard, et al.
Publicado: (2010) -
Patient considerations and clinical utility of a fixed dose combination of saxagliptin/metformin in the treatment of type 2 diabetes
por: Maffioli P, et al.
Publicado: (2011) -
Emerging utility of once-weekly exenatide in patients with type 2 diabetes
por: Goud A, et al.
Publicado: (2015)